Stanley Laman Group Ltd. Has $4.12 Million Holdings in Bruker Corporation $BRKR

Stanley Laman Group Ltd. raised its position in shares of Bruker Corporation (NASDAQ:BRKR) by 13.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 99,890 shares of the medical research company’s stock after buying an additional 12,154 shares during the period. Stanley Laman Group Ltd. owned about 0.07% of Bruker worth $4,115,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Pinnacle Bancorp Inc. bought a new stake in Bruker during the 1st quarter worth approximately $29,000. Allworth Financial LP raised its holdings in shares of Bruker by 92.4% in the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares in the last quarter. Parallel Advisors LLC grew its holdings in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after acquiring an additional 347 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Bruker during the first quarter valued at approximately $42,000. Institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

BRKR has been the topic of a number of recent research reports. Bank of America decreased their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, June 26th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a “hold” rating in a report on Tuesday, August 5th. Barclays reduced their target price on shares of Bruker from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a “buy” rating in a research report on Monday, August 4th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $51.00.

Bruker Price Performance

Shares of BRKR opened at $36.98 on Friday. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market cap of $5.61 billion, a P/E ratio of 71.12, a price-to-earnings-growth ratio of 5.35 and a beta of 1.20. The stock’s 50-day moving average price is $33.48 and its two-hundred day moving average price is $37.01. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.64.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. During the same period in the previous year, the business earned $0.52 EPS. The firm’s revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts predict that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a $0.05 dividend. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Bruker’s dividend payout ratio is currently 38.46%.

Insider Buying and Selling

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.